Healthcare: Top Picks Q1 2013 – Sanofi stays in, AZN with Fair Value upped to 3,440p jumps in with FMC, ASTRAZENECA Attractive risk-reward as new CEO comes in

BUY vs. NEUTRAL, Fair Value 3440p vs. 2860p (+13%)
News published on January Thursday 17, 2013
Share on

Attractive risk-reward as new CEO comes in (full report published today)

Among the big names in the pharmaceutical industry, AstraZeneca is obviously one of the few which carries in principle one of the most significant upsides considering its current valuation, provided the new CEO, Pascal Soriot, is able not only to present a comprehensive and clear strategy but also to package his speech in an attractive manner for the investment community to jump in as early as the beginning of 2013.

The Essentials

Everything you need to know about investment banking dedicated to growth
Recent Transactions Highlights
From M&A, to IPOs see what’s been happening at Bryan, Garnier & Co this year
Join our Team
Bryan, Garnier & Co is always looking for talent in all our divisions, at all levels
Explore our opportunities